Breaking News

Illumina shares advance on Bristol-Myers cancer drug collaboration

Illumina Inc. ILMN, -0.27% shares rose in the prolonged consultation Friday after the DNA sequencing company and Bristol-Myers Squibb Co. BMY, -0.32% introduced they will use Illumina's next-generation sequencing era to broaden cancer drugs at Bristol-Myers. Illumina shares rose 1.7% after hours, following a 0.3% decline to close at $241.44 Friday. The firms mentioned they are going to use the Illumina TruSight Oncology 500 take a look at to seek out genetic biomarkers to target in the development of cancer drugs. Bristol-Myers shares complicated 0.6% after hours, following a 0.3% decline to close at $58.65 in the common consultation.